The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Continuous treatment with FLT3 inhibitors for patients with FLT3-mutated AML undergoing alloSCT
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses treatment strategies for patients with FLT3-mutated acute myeloid leukemia (AML) who undergo allogeneic stem cell transplantation (alloSCT). She mentions that treatment with FLT3 inhibitors should be continued prior to and after alloSCT to prevent relapse, as evidenced in the QuANTUM-First study (NCT02668653). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
